Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia

Antioxidants(2021)10.3390/antiox10060956Source: DataRank Database

Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia is a research paper published in Antioxidants (2021). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.66)OA: goldTopics (24)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Mi Tian ORCID,Heath L. Bradley ORCID,Jonathan Metts ORCID,Himalee S. Sabnis ORCID,Wandi Zhu ORCID

Live enrichment

PubMed:34203664 PMC:PMC8232307 OpenAlex:https://openalex.org/W3169103251

National Institutes of Health

Grant: 1R01HL152131-01

Modulation of protein methylation to improve hematopoietic stem cell engraftment

Aflac Cancer and Blood Disorders Center

Grant: Pilot grant, no number

National Institutes of Health

Grant: 5R01DK059380-08

STAT5 Structure-Function in Hematopoiesis

FWCI

0.66

Citation Percentile

0.7%

Citation Trend

2022

2023

2025

goldLicense: cc-by

journalhttps://www.mdpi.com/2076-3921/10/6/956/pdf?version=1623898317

publisherhttps://www.mdpi.com/2076-3921/10/6/956/pdf?version=1623898317

publisherhttps://www.mdpi.com/2076-3921/10/6/956/pdf

journalhttps://doi.org/10.3390/antiox10060956

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34203664

Fields of Study

Acute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchProtein Degradation and Inhibitors0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

PimozidePharmacologyMyeloid leukemiaCancer researchBiologyChemistryMedicineNeuroscienceReactive oxygen speciesAcute myeloid leukemiaMtor InhibitorBh3 MimeticMitosoxFlt3-internal Tandem DuplicationRepurposed DrugsRM1-950ArticleTherapeutics. Pharmacology

Sustainable Development Goals

SDG 3: 3. Good health

Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia

FAIR Checklist

Authors (8)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)